Day: December 7, 2024

NEWPORT NEWS, Va., Dec. 07, 2024 (GLOBE NEWSWIRE) — HII (NYSE: HII) today christened Virginia-class submarine Arkansas (SSN 800) at the company’s Newport News Shipbuilding (NNS) division. “Today we celebrate the mighty submarine Arkansas, and we honor bravery and impact: the heroes and heroic moments that shape our future and make us who we are,” NNS President Jennifer Boykin said. “As high school students, the Little Rock Nine exhibited courage, and showed the American people what determination and perseverance look like. Their spirit guided them then, and today SSN 800 will be instilled with this same spirit of courage, determination, and resilience.” The ship’s sponsors are the six women of the historic group known as the Little Rock Nine, the first African American students to attend all-white Central High School in Little...

Admirals Group AS has entered into an agreement to sell its wholly owned subsidiary, Admirals AU PTY Ltd (Australia), a licensed investment company, to a non-related party, as part of the Admirals group’s ongoing optimization of its geographic focus. The transaction, subject to customary closing conditions, is expected to positively contribute to Admirals Group AS’s net profit and streamline its operations in alignment with its core strategy. This strategic move underscores Admirals Group AS’s commitment to delivering value by concentrating resources in key regions where it sees the strongest potential for growth and operational efficiency. Additional information:  Alexander Tsikhilov Chairman of the Management Board of Admirals Group AS alexander.tsikhilov@admirals.com  +372 6309 300 https://www.admirals.group/

Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied. 96% of patients received an infusion of fresh, fit, stem-like, early memory CD19 CAR T-cell therapy with a median vein-to-vein time of seven days, avoiding the need for cryopreservation and bridging therapy. These data reinforce the potential of Galapagos’ decentralized cell therapy manufacturing platform to deliver fresh, fit cells, fast, driving positive patient outcomes. Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 66th American...

NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition being held on December 7 –10, 2024, in San Diego, California. A poster titled “CD38-SADA, a Self-Assembling and Dis-Assembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma” characterizes the selective binding of CD38-SADA to DOTA-chelated lanthanide metals and high-avidity binding...

ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP Pivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent or chronic ITP Results underscore the safety and efficacy of rilzabrutinib and its potential as the first BTK inhibitor in ITP Rilzabrutinib is currently under regulatory review in the US and the EU Paris, December 7, 2024. Positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (ITP), a rare immune-mediated disease, reinforce the efficacy and safety of rilzabrutinib, an oral, reversible, covalent Bruton’s tyrosine kinase (BTK) inhibitor, and further...

All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to 60%, a decrease in hemoglobin S to

Hamilton, Bermuda. December 7, 2024. Avance Gas Holding Ltd. («Avance Gas» or «Company») (OSE: AGAS) refers to the announcement on August 15, 2024, regarding the sale of its VLGC fleet to BW LPG Ltd (“BW LPG” or “Buyer”) for $1,050 million. Today Avance Gas announces the seventh VLGC delivery, the 2015-built vessel Pampero. In connection with the delivery, 1.350 million shares in BW LPG were issued by the Buyer to Avance Gas. The ship mortgage has been repaid and Avance Gas expects to receive net cash proceeds of approximately $7 million. Following the delivery, Avance Gas owns 10.991 million shares in BW LPG corresponding to a 7.28% ownership share. These consideration shares have a lock-up period of 40 days from the issuance date as previously announced. Pampero is currently on a variable Time Charter expiring...

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025 – Conference Call on Saturday, December 7th at 9:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a July 5, 2024 data cutoff from the ongoing phase 1/2 trial of petosemtamab, a Biclonics® targeting EGFR and LGR5, in previously treated (2L+) patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC)....

VANCOUVER, British Columbia, Dec. 06, 2024 (GLOBE NEWSWIRE) — Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the “Company” or “Fobi”), is an industry leader in harnessing AI and data intelligence to enable digital transformation. As a result of a review by the British Columbia Securities Commission, Fobi is issuing the following press release to clarify our disclosure on the information previously included in the Company’s management information circulars (“Circular”) concerning CEO Rob Anson’s total percentage of ownership regarding direct and indirect holdings in the Company (“Shareholdings”).  The Shareholdings are calculated based on the issued and outstanding of the Company at the record date reported in each respective Circular. Total % of Issued and Outstanding     Reported in Circular Actual...

VANCOUVER, British Columbia, Dec. 06, 2024 (GLOBE NEWSWIRE) — Fobi AI Inc. (FOBI:TSXV) (FOBIF: OTCQB) (the “Company” or “Fobi”), an industry leader in harnessing AI and data intelligence to enable digital transformation, is committed to maintaining transparency and continuous communication with its stakeholders regarding the recent cease trade order (“CTO”) issued by the British Columbia Securities Commission. The Company, in collaboration with its auditors, is actively working to finalize the audit and filing of its financial statements for the fiscal year ended June 30, 2024, as well as the related management discussion and analysis (“2024 Annual Filings”). These filings were due on October 28, 2024, and the Company is dedicated to ensuring compliance with all applicable standards and regulatory requirements (“Standards”). Fobi...